stella
beta
A Database Survey to Evaluate the Safety of Immune Globulin Subcutaneous (Human), 20% Solution in Participants With Primary Immunodeficiency — Stella
Recruiting
Back to Primary Immunodeficiency Diseases (PID) trials
Trial locations
(1 site)
Japan
Takeda selected site, Tokyo, Tokyo
View full record on ClinicalTrials.gov